Aigen Investment Management LP Invests $428,000 in Inari Medical, Inc. (NASDAQ:NARI)

Aigen Investment Management LP bought a new stake in Inari Medical, Inc. (NASDAQ:NARI) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,369 shares of the company’s stock, valued at approximately $428,000.

A number of other large investors have also added to or reduced their stakes in NARI. Versor Investments LP purchased a new position in shares of Inari Medical in the 3rd quarter worth about $396,000. State of New Jersey Common Pension Fund D boosted its stake in Inari Medical by 23.7% in the third quarter. State of New Jersey Common Pension Fund D now owns 46,087 shares of the company’s stock worth $1,901,000 after buying an additional 8,830 shares in the last quarter. Covestor Ltd grew its position in Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after acquiring an additional 926 shares during the last quarter. Assetmark Inc. raised its stake in shares of Inari Medical by 5.9% during the third quarter. Assetmark Inc. now owns 19,382 shares of the company’s stock worth $799,000 after acquiring an additional 1,076 shares in the last quarter. Finally, Financial Enhancement Group LLC bought a new stake in shares of Inari Medical in the 3rd quarter worth approximately $1,155,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Down 3.0 %

Shares of Inari Medical stock opened at $49.24 on Friday. The company has a market cap of $2.88 billion, a PE ratio of -36.47 and a beta of 0.96. The business has a 50 day moving average of $45.09 and a 200 day moving average of $46.85. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Truist Financial increased their target price on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Robert W. Baird lifted their price objective on Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday, October 29th. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Stifel Nicolaus started coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft started coverage on Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $58.89.

Insiders Place Their Bets

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now owns 445,310 shares in the company, valued at $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 126,000 shares of company stock worth $5,921,390. 10.60% of the stock is currently owned by corporate insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.